文献速递腹部介入MR

钇-90放射栓塞治疗肝细胞癌的疗效评估:阅片者间变异性、与三维定量方法的比较及对临床结局的预测作用

Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes.
PubMed 文献 · Eur J Radiol · 2020-10-14

研究纳入57例患者共77个肝细胞癌病灶,比较5名放射科医生按mRECIST与LIRADS治疗反应标准评估的阅片者间一致性,并与三维定量qEASL标准对照,分析各标准对无肿瘤生存与病理坏死的预测能力。结果显示mRECIST一致性为一般,LIRADS TR为中等,qEASL预测无肿瘤生存最优,LIRADS TR预测病理坏死最优。

要点

  • mRECIST阅片者间一致性为一般(K=0.43与0.34),LIRADS TR为中等(K=0.48与0.53)。
  • qEASL预测无肿瘤生存最优:第一次随访HR 2.23(1.44-3.46),第二次随访HR 1.69(1.15-2.48)。
  • LIRADS TR在预测病理坏死方面优于其他标准。

核心结论

  • TARE后肝细胞癌疗效评估具有挑战性,mRECIST阅片者间一致性为差至中等,LIRADS TR为中等。
  • qEASL在早期识别治疗反应者和预测无肿瘤生存方面优于mRECIST,提示容积性肿瘤反应评估具有优势。
  • LIRADS TR在预测病理坏死方面优于其他标准。

研究设计与样本

  • 研究纳入57例接受TARE的肝细胞癌患者,共77个病灶。
  • 5名放射科医生在TARE后4-6周和6-9个月的MRI上记录多项影像特征并判定mRECIST与LIRADS治疗反应分类。
  • qEASL分类由另一名独立阅片者判定。
  • 采用风险回归预测临床结局。

诊断标准与关键数值

  • mRECIST阅片者间一致性第一次随访K=0.43、第二次随访K=0.34,为一般。
  • LIRADS TR阅片者间一致性第一次随访K=0.48、第二次随访K=0.53,为中等。
  • mRECIST与qEASL标准间一致性第一次随访r=0.41-0.65、第二次随访r=0.54-0.60,为中等至基本一致。
  • LIRADS TR与qEASL在所有阅片者两次随访中均相关良好,第一次随访K=0.45-0.78、第二次随访K=0.39-0.77。

临床应用与阅片要点

  • TARE后疗效评估中mRECIST阅片者间一致性有限,报告时应意识到其判读差异。
  • qEASL三维定量评估在早期识别治疗反应和预测无肿瘤生存方面似乎优于mRECIST。
  • LIRADS TR在预测病理坏死方面似乎优于其他标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the inter-reader variability in response assessment for HCC treated with radioembolization (TARE) compared with 3D quantitative criteria (qEASL); and to evaluate their role in prediction of pathological necrosis and clinical outcomes.

MATERIALS AND METHODS: 57 patients with 77 HCCs who underwent TARE were included. Five radiologists recorded multiple imaging features and assigned mRECIST/LIRADS Treatment Response (TR) categories on post-treatment MRI at 4-6 weeks and 6-9 months after TARE. qEASL categories were assigned by a separate reader. Inter-reader variability between LIRADS TR/mRECIST/qEASL were evaluated and hazards regression was used in predicting clinical outcomes.

RESULTS: Inter-reader agreement was fair for mRECIST (K = 0.43 and 0.34 at first and second follow-up respectively); moderate for LIRADS TR (K = 0.48 and 0.53 at first and second follow-up respectively). Inter-criterion agreement was moderate to substantial (r = 0.41-0.65 and r = 0.54-0.60 at first and second follow-up) for mRECIST-qEASL. LIRADS TR correlated well with qEASL for all readers at both follow-ups (K = 0.45-0.78; K = 0.39-0.77 for first and second follow-up). qEASL was the most accurate in predicting Tumor-Free Survival (TFS) on first (HR 2.23 [1.44-3.46], p < 0.001) and second (HR 1.69 [1.15-2.48], p = 0.008) follow-up. LIRADS TR was the most accurate in predicting histopathological necrosis (8 patients underwent liver transplantation and 1 patient underwent tumor resection during the period of the study).

CONCLUSIONS: HCC response assessment following TARE is challenging, resulting in poor to moderate inter-reader agreement for mRECIST, and moderate inter-reader agreement for LIRADS TR response assessment criteria. qEASL outperformed mRECIST criteria for early identification of responders and predicting TFS, suggesting an advantage in volumetric tumor response assessment. LIRADS TR outperformed other criteria in predicting pathological necrosis.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. King MJ, Tong A, Dane B, et al. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. Eur J Radiol. 2020. PMID: 33096408. doi:10.1016/j.ejrad.2020.109351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。